![Michael Gray](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Gray
Director of Finance/CFO at
UPSTREAM BIO, INC.
Net worth: 199 261 $ as of 30/06/2026
Profile
Michael Paul Gray currently works at The American Institute of Certified Public Accountants, as Member and Upstream Bio, Inc., as Chief Financial & Operating Officer from 2024.
Mr. Gray also formerly worked at X4 Pharmaceuticals, Inc., as President, Chief Executive Officer & CFO from 2018 to 2019, Arsanis, Inc., as President, CEO, Chief Financial Officer & Director from 2018 to 2022, Therapeutics Acquisition Corp., as Independent Director from 2020 to 2021, Curis, Inc., as Secretary, Chief Financial & Business Officer from 2014 to 2016, Tetraphase Pharmaceuticals, Inc., as Chief Financial Officer & Senior Vice President, Reprogenesis, Inc., as Controller from 1998 to 2000, Enliven Therapeutics, Inc., as Chief Financial & Operating Officer from 2019 to 2023, Carmot Therapeutics, Inc., as Chief Operating & Financial Officer from 2023 to 2024, and Imara, Inc., as Chief Financial & Operating Officer from 2019 to 2023.
Mr. Gray received his undergraduate degree from Bryant University and Masters Business Admin degree from F.W.
Olin Graduate School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
UPSTREAM BIO, INC. 0.05% | 16/06/2026 | 28,795 ( 0.05% ) | 199 261 $ | 30/06/2026 |
Michael Gray active positions
| Companies | Position | Start |
|---|---|---|
| UPSTREAM BIO, INC. | Director of Finance/CFO | 01/03/2024 |
The American Institute of Certified Public Accountants
 The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services Association of accountants | Corporate Officer/Principal | - |
Former positions of Michael Gray
| Companies | Position | End |
|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Director of Finance/CFO | 01/02/2024 |
| IMARA | Director of Finance/CFO | 01/03/2023 |
| ENLIVEN THERAPEUTICS, INC. | Director of Finance/CFO | 23/02/2023 |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Chief Executive Officer | 01/03/2022 |
| THES ACQU | Director/Board Member | 01/07/2021 |
Training of Michael Gray
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
56
1st degree connections
13
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Curis, Inc.
 Curis, Inc. BiotechnologyHealth Technology Develops therapeutics to treat cancer | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Arsanis, Inc.
Arsanis, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
The American Institute of Certified Public Accountants
The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services Association of accountants | Commercial Services |
Reprogenesis, Inc.
 Reprogenesis, Inc. BiotechnologyHealth Technology Produces products in urology, cardiovascular biology, plastic, and reconstructive surgery | Health Technology |
Bryant University
 Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Health Technology |
F.W. Olin Graduate School of Business
 F.W. Olin Graduate School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes novel therapeutics for patients with sickle cell disease | Health Technology |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Therapeutics Acquisition Corp.
 Therapeutics Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Upstream Bio, Inc.
 Upstream Bio, Inc. BiotechnologyHealth Technology Engages in developing treatments for inflammatory diseases | Health Technology |
Enliven Therapeutics, Inc.
 Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
- Stock Market
- Insiders
- Michael Gray
Choose MarketScreener 
